BCR and B-cell chronic lymphocytic leukemia: Based on our observation that triptolide is effective against relapsed/refractory CLL B cells, it is tempting to speculate that HSF1 inhibitors could also be used effectively against the entire spectrum of CLL patients, as it affects the BCR signaling cascade.